Skip to content

High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)

Comparative Study of Pulmonary Artery Pressure (PAP) Assessed by Echocardiography in Patients With High Altitude Pulmonary Hypertension (HAPH) Permanently Residing Above 2500 Meters When Assessed Near Resident High Altitude (HA) at 3200 m vs. at Low Altitude (LA) at 760 m

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06489704
Enrollment
24
Registered
2024-07-08
Start date
2024-07-02
Completion date
2024-09-27
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Altitude Pulmonary Hypertension

Keywords

Pulmonary Hypertension, Hypoxia, High Altitude, Pulmonal Arterial Pressure

Brief summary

To study the effect of relocation from 3200 m (Aksay) to 760 m (Bishkek) in patients with high altitude pulmonary hypertension (HAPH) who permanently live \>2500 m on pulmonary artery pressure (PAP)

Detailed description

This research in highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA \>30 mmHg who permanently live at HA \>2500 m will have pulmonary arterial pressure (PAP) assessed by echocardiography near their living altitude in Aksay at 3200 m and at 760 m in Bishkek the day after the first and the seventh night after relocation.

Interventions

OTHEREchocardiography

Echocardiography will be performed according to clinical standards

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Each highlander with HAPH will perform a echocardiography at high altitude (HA, 3200 m) and day 2 and day 7 at low altitude (LA, 760 m) according to a prospective study design

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Permanently living \>2500 m * HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m * Written informed consent

Exclusion criteria

* Highlanders who cannot follow the study investigations, * Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years. * Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months * Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Design outcomes

Primary

MeasureTime frameDescription
Change in Pulmonary artery Pressure (PAP) after the first night at 760 m (LA) vs at 3200 m (HA)day 2 at 760 m vs. 3200 mChange in RV/RA in mmHg assessed by echocardiography between LA (760 m) vs High altitude (3200 m)

Secondary

MeasureTime frameDescription
Change in Pulmonary artery Pressure (PAP) after seven nights at 760 m (LA) vs at 3200 m (HA)day 7 at 760 m vs. 3200 mChange in RV/RA in mmHg assessed by echocardiography between LA (760 m) vs High altitude (3200 m)
Cardiac output at 760 m (LA) vs at 3200 m (HA)day 2 and 7 at 760 m vs. 3200 mChange in cardiac output in l/min assessed by echocardiography between LA (760 m) vs HA (3200 m)
Tricuspid pressure gradient by echocardiography at 760 m (LA) vs at 3200 m (HA)day 2 and 7 at 760 m vs. 3200 mTricuspid pressure gradient assessed by echocardiography between LA (760 m) vs HA (3200 m)
Tricupsid annular plane systolic excursion by echocardiography at 760 m (LA) vs at 3200 m (HA)day 2 and 7 at 760 m vs. 3200 mTricupsid annular plane systolic excursion assessed by echocardiography between LA (760 m) vs HA (3200 m)
pH by arterial blood gases at 760 m (LA) vs at 3200 m (HA)day 2 and 7 at 760 m vs. 3200 mChange in pH by arterial blood gases assessed between LA (760 m) vs HA (3200 m)
partial pressure of oxygen (PaO2) by arterial blood gases at 760 m (LA) vs at 3200 m (HA)day 2 and 7 at 760 m vs. 3200 mChange in partial pressure of oxygen (PaO2) assessed by arterial blood gases between LA (760 m) vs HA (3200 m)
partial pressure of carbon dioxide (PaCO2) by arterial blood gases at 760 m (LA) vs at 3200 m (HA)after the first and seventh night at LAChange in partial pressure of carbon dioxide (PaCO2) assessed by arterial blood gases partial pressure of carbon dioxide (PaCO2) between LA (760 m) vs HA (3200 m)
Change in right to left heart diameter ratio at 760 m (LA) vs at 3200 m (HA)day 2 and 7 at 760 m vs. 3200 mChange in right to left heart diameter ratio assessed by echocardiography between LA (760 m) vs HA (3200 m)
Change in right atrial area at 760 m (LA) vs at 3200 m (HA)day 2 and 7 at 760 m vs. 3200 mChange in right atrial area by echocardiography between LA (760 m) vs HA (3200 m)
Change in right heart strain at 760 m (LA) vs at 3200 m (HA)day 2 and 7 at 760 m vs. 3200 mChange in right heart strain by echocardiography between LA (760 m) vs HA (3200 m)
Change in ECG morphology at 760 m (LA) vs at 3200 m (HA)day 2 and 7 at 760 m vs. 3200 mChange in ECG morphology and QT-interval by 12-lead ECG between LA (760 m) vs HA (3200 m)

Countries

Kyrgyzstan

Contacts

PRINCIPAL_INVESTIGATORTalant M Sooronbaev, Prof. Dr.

National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

PRINCIPAL_INVESTIGATORSilvia Ulrich, Prof. Dr.

University Hospital Zurich, Department of Pulmonology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026